A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival

Siyuan Zheng, Jun Fu, Rahulsimham Vegesna, Yong Mao, Lindsey Heathcock, Wandaliz Torres‐García, Ravesanker Ezhilarasan(The University of Texas MD Anderson Cancer Center), Shuzhen Wang, Aaron McKenna(Broad Institute), Lynda Chin(The University of Texas MD Anderson Cancer Center), Cameron Brennan(Memorial Sloan Kettering Cancer Center), W.K. Alfred Yung, John N. Weinstein(The University of Texas MD Anderson Cancer Center), Kenneth Aldape, Erik P. Sulman(The University of Texas MD Anderson Cancer Center), Ken Chen, Dimpy Koul, Roel G.W. Verhaak
Genes & Development
June 24, 2013
Cited by 79Open Access
Full Text

Abstract

With the advent of high-throughput sequencing technologies, much progress has been made in the identification of somatic structural rearrangements in cancer genomes. However, characterization of the complex alterations and their associated mechanisms remains inadequate. Here, we report a comprehensive analysis of whole-genome sequencing and DNA copy number data sets from The Cancer Genome Atlas to relate chromosomal alterations to imbalances in DNA dosage and describe the landscape of intragenic breakpoints in glioblastoma multiforme (GBM). Gene length, guanine-cytosine (GC) content, and local presence of a copy number alteration were closely associated with breakpoint susceptibility. A dense pattern of repeated focal amplifications involving the murine double minute 2 (MDM2)/cyclin-dependent kinase 4 (CDK4) oncogenes and associated with poor survival was identified in 5% of GBMs. Gene fusions and rearrangements were detected concomitant within the breakpoint-enriched region. At the gene level, we noted recurrent breakpoints in genes such as apoptosis regulator FAF1. Structural alterations of the FAF1 gene disrupted expression and led to protein depletion. Restoration of the FAF1 protein in glioma cell lines significantly increased the FAS-mediated apoptosis response. Our study uncovered a previously underappreciated genomic mechanism of gene deregulation that can confer growth advantages on tumor cells and may generate cancer-specific vulnerabilities in subsets of GBM.


Related Papers

No related papers found

Powered by citation graph analysis